Figure 3From: FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms Overall survival for genotypes C and H of the rs25648 polymorphism for colorectal cancer patients with FOLFIRI® and bevacizumab in first-line treatment (with 95% confidence interval, CI). Back to article page